Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evogene Ltd Ord (EVGN)

Evogene Ltd Ord (EVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,341
  • Shares Outstanding, K 5,365
  • Annual Sales, $ 3,850 K
  • Annual Income, $ -8,490 K
  • EBIT $ -14 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.39
  • Price/Sales 1.07
  • Price/Cash Flow N/A
  • Price/Book 0.34
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.92
  • Most Recent Earnings $-0.61 on 03/05/26
  • Next Earnings Date 05/20/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7200 +9.72%
on 03/30/26
0.9700 -18.56%
on 03/23/26
-0.0740 (-8.56%)
since 03/02/26
3-Month
0.7200 +9.72%
on 03/30/26
1.2400 -36.29%
on 02/04/26
-0.3400 (-30.09%)
since 01/02/26
52-Week
0.7200 +9.72%
on 03/30/26
2.4200 -67.36%
on 06/10/25
-0.4800 (-37.80%)
since 04/02/25

Most Recent Stories

More News
Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Today, castor oil is a premium sustainable industrial feedstock for bio-based products

EVGN : 0.7907 (-2.26%)
Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Conference will be held at Lisbon, Portugal - March 23–25, 2026

EVGN : 0.7907 (-2.26%)
Evogene: Q4 Earnings Snapshot

Evogene: Q4 Earnings Snapshot

EVGN : 0.7907 (-2.26%)
Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

Conference call and webcast: today, March 05, 2026, 9:00 AM ET

EVGN : 0.7907 (-2.26%)
Evogene Releases CEO Letter to Shareholders

Updating on Strategic Progress and Outlook

EVGN : 0.7907 (-2.26%)
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

Zoom conference call scheduled for March 5, 2026, 9:00 AM ET

EVGN : 0.7907 (-2.26%)
Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

Aiming to introduce a new therapeutic strategy for overcoming chemotherapy resistance in lung cancer due to increased expression of cellular pathways

EVGN : 0.7907 (-2.26%)
Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

The collaboration is supported by a pan-European EUREKA grant, with participation of the Weizmann Institute of Science

EVGN : 0.7907 (-2.26%)
Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

REHOVOT, Israel and BOSTON , Feb. 10, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene" or the "Company"), a pioneering computational chemistry company, specializing in the...

EVGN : 0.7907 (-2.26%)
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

The new collaboration is expected to accelerate, scale and advance small-molecule discovery and optimization for pharmaceutical and agricultural products

EVGN : 0.7907 (-2.26%)

Business Summary

Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene...

See More

Key Turning Points

3rd Resistance Point 0.8535
2nd Resistance Point 0.8327
1st Resistance Point 0.8209
Last Price 0.7907
1st Support Level 0.7883
2nd Support Level 0.7675
3rd Support Level 0.7557

See More

52-Week High 2.4200
Fibonacci 61.8% 1.7706
Fibonacci 50% 1.5700
Fibonacci 38.2% 1.3694
Last Price 0.7907
52-Week Low 0.7200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.